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ABSTRACT
Background. Patients with chronic kidney disease (CKD) are at
risk of progression to end-stage renal disease and cardiovascular
disease. Data from other populations and animal experiments
suggest that neprilysin inhibition (which augments the natriuret-
ic peptide system) may reduce these risks, but clinical trials
among patients with CKD are required to test this hypothesis.
Methods. UK Heart and Renal Protection III (HARP-III) is a
multicentre, double-blind, randomized controlled trial compar-
ing sacubitril/valsartan 97/103 mg two times daily (an angioten-
sin receptor–neprilysin inhibitor) with irbesartan 300 mg one
time daily among 414 patients with CKD. Patients ≥18 years of
age with an estimated glomerular ﬁltration rate (eGFR) of ≥45
but <60 mL/min/1.73 m2 and urine albumin:creatinine ratio
(uACR) >20 mg/mmol or eGFR ≥20 but <45 mL/min/1.73 m2
(regardless of uACR) were invited to be screened. Following a
4- to 7-week pre-randomization single-blind placebo run-in
phase (during which any current renin–angiotensin system inhi-
bitors were stopped), willing and eligible participants were ran-
domly assigned either sacubitril/valsartan or irbesartan and
followed-up for 12 months. The primary aim was to compare
the effects of sacubitril/valsartan and irbesartan on measured
GFR after 12 months of therapy. Important secondary outcomes
include effects on albuminuria, change in eGFRover time and the
safety and tolerability of sacubitril/valsartan in CKD.
Results. Between November 2014 and January 2016, 620
patients attended a screening visit and 566 (91%) entered the
pre-randomization run-in phase. Of these, 414 (73%) partici-
pants were randomized (mean age 63 years; 72% male). The
mean eGFR was 34.0 mL/min/1.73 m2 and the median uACR
was 58.5 mg/mmol.
Conclusions. UK HARP-III will provide important informa-
tion on the short-term effects of sacubitril/valsartan on renal
function, tolerability and safety among patients with CKD.
Keywords: cardiovascular disease, chronic kidney disease, ne-
prilysin, progression
INTRODUCTION
Chronic kidney disease (CKD) affects between 2 and 17% of the
general population (depending on the country) [1, 2] and is as-
sociated with increased risks of progression to end-stage renal
disease (ESRD) andmorbidity andmortality from cardiovascu-
lar disease (CVD) [3, 4]. Renin–angiotensin system (RAS) inhi-
bitors [angiotensin-converting enzyme inhibitors (ACEis) and
angiotensin receptor blockers (ARBs)] have been shown to re-
duce the risk of ESRD in patients with proteinuric CKD [5–8],
but despite such treatments, patients remain at signiﬁcant risk
of progression to ESRD and CVD.
The natriuretic peptide (NP) system is a neurohormonal sys-
tem that has a variety of potentially beneﬁcial functions, includ-
ing natriuresis, diuresis, vasodilatation and counterregulation
of RAS [9, 10]. The NP system can be augmented by inhibiting
the main enzyme responsible for degrading NPs, namely
neprilysin [or neutral endopeptidase (NEP)] [10]. NEP is
a membrane-bound zinc-containing metalloproteinase [11]© The Author 2016. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
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that also degrades other peptides, including angiotensin II,
bradykinin, endothelin and substance P [12]. However, isolated
NEP inhibition (NEPi) leads to reﬂex RAS activation, and inhi-
bits angiotensin II breakdown (counteracting any potentially
beneﬁcial effects) and therefore NEPi must be combined with
RAS inhibition.
As NEPi and ACEi both inhibit bradykinin degradation,
their combination is associated with substantially elevated
bradykinin levels that cause unacceptable rates of angioedema
[13]. ARBs do not inhibit bradykinin degradation and can be
safely combined with NEPi [creating a new class of drugs called
angiotensin receptor–neprilysin inhibitors (ARNis)]. Sacubi-
tril/valsartan (previously known as LCZ696) is the ﬁrst drug
in this new class, combining valsartan with sacubitril
[(AHU377) a prodrug that is metabolized via esterases to the
active NEPi sacubitrilat (LBQ657)]. Sacubitril/valsartan 97/
103 mg provides equivalent plasma concentrations of valsartan
as oral valsartan 160 mg [14].
In a 5/6 nephrectomy model, treatment with combined
NEP/RAS inhibition was associated with greater reductions in
proteinuria and glomerulosclerosis compared with RAS inhib-
ition alone [15, 16]. Micropuncture studies also demonstrated
NEPi led to greater reductions in capillary glomerular pressure
[15]. Among patients with heart failure, trials comparing sacu-
bitril/valsartan with either ACEi or ARB have suggested that the
estimated glomerular ﬁltration rate (eGFR) of patients allocated
sacubitril/valsartan declined less than those assigned ACEi or
ARB [17, 18]. Sacubitril/valsartan also reduced blood pressure
more than equivalent doses of valsartan in trials among patients
with elevated blood pressure [19]. Trials in heart failure popu-
lations suggest NEPi might increase albuminuria [18, 20], but
this effect was not observed in patients with hypertension
[19] and baseline albuminuria was very low in all these trials.
Overall, these data raise the hypothesis that treatment with an
ARNi may be superior to either ACEi or ARB alone in slowing
the progression of CKD.
The United Kingdom (UK) Heart and Renal Protection III
(HARP-III) trial (ISRCTN11958993) was designed to provide
information on the short-term efﬁcacy (in terms of effect on
renal function), tolerability and safety of sacubitril/valsartan
among patients with CKD. The trial will also assess the effects
of sacubitril/valsartan on albuminuria, blood pressure and bio-
markers of kidney and cardiac damage.
MATERIALS AND METHODS
Study design
UK HARP-III is a double-blind, multicentre, randomized
controlled trial comparing sacubitril/valsartan 97/103 mg two
times daily versus irbesartan 300 mg one time daily among at
least 400 participants ≥18 years of age with stages 3 and 4
CKD. Irbesartan 300 mg was selected as the comparator, as it
has been shown to reduce the risk of ESRD among patients
with diabetic kidney disease and is licensed for the treatment
of proteinuric CKD [6, 21]. Participants were randomly allo-
cated to receive sacubitril/valsartan or irbesartan and will be
followed up for 1 year (Figure 1). The primary aim of UK
HARP-III is to assess the effect of sacubitril/valsartan 97/103
mg two times daily versus irbesartan 300 mg one time daily
on measured glomerular ﬁltration rate (mGFR) at 12 months.
Important secondary outcomes include the effect on urine al-
bumin:creatinine ratio (uACR) and eGFR. All the secondary
and tertiary assessments are shown in Figure 2 and further de-
tails are available in the data analysis plan (see Supplementary
data). A summary of substantial amendments to the protocol is
provided in the Supplementary data.
Eligibility
To fulﬁl the inclusion criteria, patients need to be ≥18 years
of age and have either an eGFR ≥45 but <60 mL/min/1.73 m2
with a uACR >20 mg/mmol or eGFR ≥20 but <45 mL/min/
F IGURE 1 : UK HARP-III trial design.
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1.73 m2 (regardless of uACR). The exclusion criteria were de-
signed to identify patients for whom the safety of sacubitril/val-
sartan or irbesartanmay have been a concern. The full eligibility
criteria are shown in Figure 3.
Study enrolment and randomization
Identiﬁcation and invitation. After relevant ethics [Notting-
ham Research Ethics Committee 2 (13/EM/0434)] and regula-
tory approvals had been obtained, sites were established in UK
renal units. Site staff identiﬁed potentially eligible patients from
hospital electronic databases, mailed these individuals an invi-
tation letter and a copy of the patient information sheet and
called them ∼1 week later to discuss the trial in more detail, an-
swer any questions they might have and to see whether they
were interested in participating. Those individuals interested
in participating were invited to attend a screening visit.
Screening. At the screening visit, eligibility was assessed and
written informed consent was obtained from eligible indivi-
duals. All data were recorded directly into a bespoke Internet-
based electronic case report form system. Relevant details of
their medical history (including primary renal diagnosis, pres-
ence of diabetes mellitus and prior CVD) were recorded by
trained research nurses and their height, weight and blood pres-
sure were measured. Blood pressure was measured and re-
corded three times using an Omron M6 automated digital
sphygmomanometer after sitting for at least 5 minutes. Willing
and eligible patients entered the pre-randomization run-in
phase. Samples of blood and urine were sent to the local hos-
pital laboratory for conﬁrmation of eligibility. If the results
were considered inaccurate (e.g. haemolysed sample) by the
local study staff the samples could be repeated once, but if the
results did not conﬁrm eligibility the participant was withdrawn
from the run-in phase.
Pre-randomization run-in. The aims of the pre-
randomization run-in phase were (i) to ‘wash out’ any ACEi
prior to introduction of NEPi, (ii) to allow a comparison of
the acute effects of the study treatments on GFR and (iii) to re-
duce the rate of post-randomization discontinuation of study
treatment and to produce a consequent improvement in the
trial’s statistical sensitivity [22]. Following the screening visit,
any current ACEi and/or ARB that the participant was taking
was stopped and the participant entered the 4- to 7-week single-
blind pre-randomization run-in phase, during which they were
asked to take one placebo sacubitril/valsartan tablet and one
placebo irbesartan capsule once daily. If elevated blood pressure
became a concern during the run-in phase, local investigators
were advised to titrate up or start additional anti-hypertensive
medications, but to avoid an ACEi, ARB or direct renin inhibi-
tor (DRI). The choice of additional anti-hypertensive therapy
remained at the discretion of the responsible clinician. Partici-
pants could withdraw from the trial for any reason during this
run-in phase. Participants who did not withdraw returned 4–7
weeks later and had their GFR measured and attended a ran-
domization visit. GFR was measured using a standard
51Cr-EDTA technique, although if this was not available at
the site, other methods (99mTc-DTPA or iohexol) could be
used with the agreement of the coordinating centre. In willing
participants, a 24-hour collection of urine for albumin and so-
dium quantiﬁcation was also obtained.
Randomization visit. Participants were not eligible for ran-
domization if themean of their second and thirdmeasurements
of systolic blood pressure was <110 mmHg (or <130 mmHg
with symptoms of hypotension) or if they reported an adverse
event they believed to be related to their run-in treatment. Par-
ticipants who remained willing and eligible were then randomly
allocated in a 1:1 ratio to receive either sacubitril/valsartan or
irbesartan. Participants were randomized by an Internet-based
system using aminimization algorithm to ensure balance of im-
portant predictors of renal progression, including age, sex, sys-
tolic blood pressure, eGFR, uACR and the presence or absence
of diabetes mellitus.
At the randomization visit, run-in treatment was collected
and willing and eligible participants were issued two bottles
of study treatments: one containing sacubitril/valsartan 97/
103 mg or placebo tablets and the other containing irbesartan
150 mg or placebo capsules (therefore a double-dummy tech-
nique to protect blinding). Participants were initially instructed
to take one tablet and one capsule daily in the morning (i.e. ei-
ther sacubitril/valsartan 97/103 mg plus placebo irbesartan or
placebo sacubitril/valsartan plus irbesartan 150 mg). Blood
and urine samples were collected for the local analysis of cre-
atinine, electrolytes, liver function tests and uACR and others
were prepared for central analysis (Table 1).
Post-randomization follow-up
Randomization is now complete and all participants are in
follow-up. In order to check potassium and renal function
after starting study treatment, participants attend their study
clinic or local primary care physician at 2 weeks after random-
ization for a blood sample. If these results are satisfactory, study
treatments are increased to either sacubitril/valsartan 97/103
mg two times daily plus two capsules of placebo irbesartan
one time daily or one tablet of placebo sacubitril/valsartan
two times daily plus irbesartan 300 mg one time daily.
F IGURE 2 : UK HARP-III trial outcomes.
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Follow-up assessments. Study follow-up visits are scheduled
at 1, 3, 6, 9 and 12 months after randomization. At all visits,
study staff systematically seek the information on all serious ad-
verse events, any non-serious adverse events considered by par-
ticipants to be related to study treatment; and on symptoms of
hepatitis. Compliance with study treatment is assessed and par-
ticipants unable to tolerate the maximum dose of study treat-
ments are encouraged to continue on the lower dose of study
drug (i.e. sacubitril/valsartan 97/103 mg or irbesartan 150 mg
daily) for the remainder of the trial. If relevant, a reason for dis-
continuation or dose reduction is recorded. Participants pre-
scribed contraindicated medications (ACEi, ARB or DRI)
have their randomized treatment stopped. Weight and blood
pressure are measured (three times after sitting for at least 5
minutes) at all visits. In both treatment groups, blood pressure
is to be controlled according to the Kidney Disease: Improving
Global Outcomes guidelines [23], with the initiation and choice
of additional anti-hypertensive treatment being at the discre-
tion of the responsible clinician. Within the 2 weeks before
their 12-month visit participants have their second GFR meas-
urement (using the same method as at baseline). Copies of
results of both measurements of GFR are sent to the coordinat-
ing centre so the results entered by site staff can be veriﬁed by
clinical study staff blind to the treatment allocation.
Biological samples and safety monitoring. At each follow-
up visit, blood and urine samples are sent to the local hospital
laboratory for creatinine, electrolytes, liver function tests (bili-
rubin, alanine or aspartate transaminase and alkaline phosphat-
ase) and uACR. In addition, at the 3-, 6- and 12-month visits,
samples are also taken for central analysis. EDTA samples are
centrifuged and the plasma aliquoted into Cryovials, which
are stored locally (with Cryovials of urine) at or below −20°C
prior to transfer to the central laboratory in Oxford, UK,
where they are stored at−80°C. Themain plasma analytes mea-
sured at the central laboratory are creatinine, cardiac and in-
ﬂammatory biomarkers and the urine analytes include
albumin and markers of tubular damage and function [includ-
ing kidney injury molecule 1, neutrophil gelatinase-associated
lipocalin, β2-microglobulin and retinol binding protein;
Table 1]. Participants are asked not to take their morning
dose of study treatment on the day of their 3-month visit (at
F IGURE 3 : Inclusion and exclusion criteria. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.
O
R
IG
IN
A
L
A
R
T
IC
L
E
4 The UK HARP-III Collaborative Group
this visit only) and the date and time of the last dose is recorded,
as these samples are to be used for pharmacokinetic analyses.
The results of local samples are entered into the trial data-
base once available and reviewed daily by a trained clinician
at the coordinating centre. If the potassium is >5.5 mmol/L, ala-
nine or aspartate transaminase >2× the upper limit of normal or
if the eGFR has fallen >25% from the previous value, then the
trial protocol provides advice on further tests and study treat-
ment (see Supplementary data).
Monitoring
Prior to starting recruitment, study staff received training in
the study procedures and the web-based data collection system
at the coordinating centre. Recruitment rates, adherence to trial
procedures and completeness of follow-up data are monitored
closely by staff at the coordinating centre. All sites have at least
one on-site monitoring visit, with further visits as indicated by
the results of central monitoring of the data. An independent
data monitoring committee (see Supplementary data) regularly
reviews unblinded interim analyses of all relevant data.
Statistical considerations
Sample size. The chief aim of this study is to compare mGFR
between the two treatment groups at the ﬁnal follow-up visit.
Analysis of covariance (ANCOVA) compares mean follow-up
mGFR between treatment groups after adjustment for baseline
mGFR [24]. Assuming a between-person standard deviation
(SD) in mGFR of 15 mL/min/1.73 m2 and a correlation be-
tween an individual’s baseline and follow-up mGFR of 0.8, ran-
domization of 400 participants will provide at least 80% power
(at 2 P = 0.05) to detect a difference inmGFR at the ﬁnal follow-
up (adjusted for baseline values) of 3mL/min/1.73 m2 (the cho-
sen minimum clinically meaningful difference), even if 15% of
participants discontinue allocated study treatment [20].
Statistical analysis. All analyses will involve comparing out-
comes during the scheduled treatment period among all those
participants allocated at randomization to receive sacubitril/
valsartan 97/103 mg two times daily versus all those allocated
to receive irbesartan 300 mg one time daily [i.e.
intention-to-treat (ITT) analyses] [25, 26]. Comparisons of
continuous outcomes (including the primary outcome) be-
tween the allocated treatment arms will be performed using
ANCOVA adjusted for each patient’s value at baseline [27]. If
continuous outcomes are not normally distributed, then appro-
priate transformations (e.g. log transformation) will be made.
Multiple imputation techniques will be used to account for
any missing data in the primary and secondary outcomes
[28]. Further details are provided in the data analysis plan
(see Supplementary data).
RESULTS
Study sites were established in 24 renal units in theUK. Between
November 2014 and January 2016 a total of 620 patients at-
tended the study screening visits and 566 (91%) entered the pre-
randomization run-in (Figure 4).
Pre-randomization run-in
A total of 138 participants withdrew from the pre-
randomization run-in before attending a randomization visit
(Table 2A). The most common medical reason for withdrawal
from run-in was that the results from blood and urine samples
taken at the screening visit did not conﬁrm the participant’s eli-
gibility (Table 2A). Adverse events were uncommon and four
participants were withdrawn because of a serious adverse
event (myocardial infarction, septic shock and two cases of
pneumonia).
In addition, 14 individuals attended a randomization visit
but were not eligible to be randomized: the most common rea-
son for this was their blood pressure being too low (Table 2B).
Overall, 152 (27%) of the 566 individuals who entered the pre-
randomization single-blind placebo run-in phase were not sub-
sequently randomized.
Baseline characteristics of randomized participants
A total of 414 people were randomized (Figure 4). The mean
age was 63 (SD 14) years and 298 (72%) were male (Table 3).
The mean systolic blood pressure was 146 (SD 16) mmHg at
randomization (i.e. after 4–7 weeks of withdrawal of any prior
ACEi or ARB). Based on results from the local laboratories, the
mean eGFR was 34.0 (SD 10.6) mL/min/1.73 m2 and the me-
dian uACR was 58.5 (interquartile range 12.5–156.3) mg/
mmol. Central laboratory assays will be conducted at the end
of the study. About half of randomized participants had either
glomerular [111 (27%)] or diabetic [83 (20%)] kidney disease
and 165 (40%) patients reported diabetes mellitus at baseline.
The median 5-year risk of ESRD (calculated using a validated
risk calculator [29] was 16.5%, and 62% of participants had a
5-year risk >10%.
Table 1. Planned central laboratory blood and urine analyses
Analyte Time point
Randomization 3
months
6
months
12
months
EDTA plasma samples
Creatinine ▪ ▪ ▪ ▪
Albumin ▪ ▪ ▪
Troponin-I ▪ ▪ ▪
NT-proBNP ▪ ▪ ▪
CRP ▪ ▪ ▪
IL-6 ▪ ▪ ▪
Urine samples
Albumin:creatinine
ratio
▪ ▪ ▪ ▪
KIM-1 ▪ ▪ ▪
NGAL ▪ ▪ ▪
cGMP ▪ ▪ ▪
β-2-microglobulin ▪ ▪ ▪
Retinol binding
protein
▪ ▪ ▪
NT-proBNP, N-terminal prohormone brain natriuretic peptide; CRP, C-reactive protein;
IL-6, interleukin 6; KIM-1, kidney injury molecule 1; NGAL, neutrophil
gelatinase-associated lipocalin; cGMP, cyclic guanosine monophosphate.
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DISCUSSION
The UK HARP-III trial has recruited 414 participants with
CKD and will provide information on the short-term effects
of sacubitril/valsartan on the change in kidney function
(using mGFR) and the tolerability and safety of the drug com-
pared with irbesartan in people with CKD. The trial will also
provide information on the effects of sacubitril/valsartan on al-
buminuria, blood pressure and other biomarkers of both kidney
and cardiac function. These results are important because sacu-
bitril/valsartan has now entered routine clinical practice as a
treatment for heart failure with reduced ejection fraction
(HFrEF) [30], and many of these patients also have CKD.
Moreover, NEPi has the potential to be a useful treatment for
CKD itself.
Large randomized trials of interventions to slow the progres-
sion of CKD are required since currently available treatments
do not prevent ESRD in all patients with CKD. Although
ACEis and ARBs reduce the risk of progression of proteinuric
diabetic and non-diabetic kidney disease, their effect (like most
medical treatments) is moderate. For example, in proteinuric
diabetic kidney disease, irbesartan reduced the risk of ESRD,
doubling of creatinine or death from any cause by 20% com-
pared with placebo {hazard ratio [HR] 0.80 [95% conﬁdence
interval (CI) 0.66–0.97]; P = 0.02}, but this composite outcome
still occurred in nearly one-third of those allocated irbesartan
(and 14% reached ESRD) during the mean 2.6 years of follow-
up [6]. Other strategies to reduce the risk of renal progression
have either been ineffective, hazardous or both [31–33]. Nepri-
lysin inhibition appears to be effective in rat models of CKD
[15, 16, 34], but these are poorly predictive of efﬁcacy in hu-
mans [35, 36]. In addition, sacubitril/valsartan has been
shown to increase albuminuria in trials among patients with
heart failure (who typically have very low baseline albuminuria)
[18, 20]. NPs (particularly atrial NP) cause afferent arteriolar
vasodilatation [37, 38] that may lead to increased intraglomer-
ular pressure and hyperﬁltration, which would be detrimental
to the kidney. However, NEPi also disturbs degradation of other
F IGURE 4 : Trial proﬁle: flow of participants through the trial. *Indicates that participants may have more than one reason.
Table 2. Reasons for (A) withdrawal during run-in and (B) ineligibility at a
randomization visit
(A) n (%)
Number entering run-in 566
Adverse event
Serious adverse event 4 (3)
Non-serious adverse reaction 7 (5)
Other reason
Ineligible on laboratory results sent at screening visit 59 (43)
Participant wishes 16 (12)
Medical advice 13 (9)
Other non-medical reason 39 (28)
Total withdrawn during Run-in 138 (100)
(B)
Number attending randomization visit 428
Adverse event
Serious adverse event 0 (0)
Non-serious adverse reaction 3 (21)
Other reason
Blood pressure too low 9 (64)
Other 2 (14)
Total ineligible at randomization visit 14 (100)
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vasoactive peptides, so the net effect of NEPi on glomerular
haemodynamics is uncertain, and in rat models at least, it ap-
pears to be favourable [15, 16, 34]. NPs may alter glomerular
permeability and/or tubular reabsorption of protein, which
may lead to albuminuria without hyperﬁltration, the conse-
quences of which are uncertain. UK HARP-III is the ﬁrst trial
of NEPi in humans with CKD and the measurements of GFR,
albuminuria and other markers of kidney function and damage
will help to resolve these uncertainties.
Most patients with CKDdo not progress to ESRD [39], but are
at high risk of CVD [4]. Lowering low-density lipoprotein choles-
terol has been shown to clearly reduce the risk of atherosclerotic
vascular disease inCKD [40].However, as renal function declines,
the pattern of CVD changes from atherosclerotic disease (i.e.
myocardial infarction, ischaemic stroke) to non-atherosclerotic
disease (characterized by arteriosclerosis and structural heart dis-
ease, which manifests clinically similarly to heart failure, with a
high incidence of sudden cardiac death) [4, 41–43], but effective
treatments for non-atherosclerotic disease are not yet available.
Lowering blood pressure in patients with CKD appears to reduce
the risk of awide variety of cardiovascular events, but residual risk
remains [44]. The similarities in the manifestation of non-
atherosclerotic disease observed in CKD and heart failure suggest
that treatments that are effective in heart failure may well also be
effective at reducing cardiovascular risk among patients with
CKD. In the Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart
Failure (PARADIGM-HF) trial, sacubitril/valsartan reduced the
risk of cardiovascular mortality or hospitalization for heart failure
by 20% [HR 0.80 (95% CI 0.73–0.93) P < 0.001] compared with
enalapril, with similar effects observed among participants with
and without CKD at baseline [45]. These data suggest that
NEPi would be an ideal candidate to test among patients with
CKD. Nevertheless, most patients with CKD have a normal ejec-
tion fraction [41, 43], and treatments that improve outcomes in
HFrEF do not necessarily improve outcomes in patients with
heart failure with preserved ejection fraction [46, 47], so direct
evidence is needed. NEPi has improved cardiac biomarkers
(e.g. troponin, N-terminal prohormone brain NP in trials in
heart failure [18, 48], so the effects of NEPi on these cardiac bio-
markers in people with CKD will also be of interest.
NEPi has the potential to improve both renal and cardiovas-
cular outcomes among patients with CKD. The UK HARP-III
trial will provide important information on the efﬁcacy, safety
and tolerability of sacubitril/valsartan in people with CKD. Re-
sults are anticipated in 2017.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
ACKNOWLEDGEMENTS
The most important acknowledgement is to the participants in
the study and to the collaborators listed in the appendix. The
Table 3. Baseline characteristics of UK HARP-III participants
Baseline characteristic All participants (n = 414)
Age (years) 63 ± 14
<50 73 (18)
≥50–70 196 (47)
≥70 145 (35)
Gender
Male 298 (72)
Female 116 (28)
Ethnicity
White 377 (91)
Black 7 (2)
South Asian 18 (4)
Other 12 (3)
Prior disease
Coronary heart disease 55 (13)
Cerebrovascular disease 31 (7)
Peripheral arterial disease 44 (11)
Heart failure 17 (4)
Diabetes 165 (40)
Systolic blood pressure (mmHg) 146 ± 16
<140 149 (36)
≥140–160 180 (43)
≥160 85 (21)
Diastolic blood pressure (mmHg) 81 ± 11
<80 191 (46)
≥80–90 133 (32)
≥90 90 (22)
Body mass index (kg/m2) 30.6 ± 6.2
<25 68 (16)
≥25–30 147 (36)
≥30 195 (47)
Not available 4 (1)
Medication
Antiplatelet therapy 138 (33)
Oral anticoagulant 28 (7)
Diuretic 164 (40)
Calcium channel blocker 207 (50)
β-blocker 112 (27)
α-blocker 112 (27)
LDL-lowering agent 263 (64)
Prior use of ACEi or ARB
Yes 339 (82)
No 75 (18)
CKD-EPI eGFR (mL/min/1.73 m2) 34.0 ± 10.6
<30 169 (41)
≥30–45 176 (43)
≥45 64 (15)
Not available 5 (1)
Urine albumin:creatinine ratio (mg/mmol) 58.5 (12.5–156.3)
<3 48 (12)
≥3–< 30 88 (21)
≥30 251 (61)
Not available 27 (7)
Primary renal diagnosis
Glomerular disease 111 (27)
Tubulointerstitial disease 50 (12)
Diabetic kidney disease 83 (20)
Hypertensive/renovascular disease 42 (10)
Other systemic diseases affecting the kidneys 3 (1)
Familial/hereditary nephropathies 43 (10)
Miscellaneous renal disorders 9 (2)
Unknown 73 (18)
Recorded at randomization visit unless otherwise stated. Values are given as n
(%), mean ± SD or median (interquartile range).
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; LDL,
low-density lipoprotein.
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